The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
List view / Grid view
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.
Results of an international collaboration show promise for the future of motor neurone disease treatment efforts, as protective gene is identified.
The G-protein coupled receptor Frizzled, implicated in diseases like cancer, can be targeted with small molecules which could provide the basis for anti-cancer therapeutics, according to researchers.
New findings using CRISPR have shown that the IL-4 and IL-13 proteins can protect the body against inflammation from autoimmune diseases.
A new study has demonstrated that the enzyme proprotein convert subtilisin/kexin 6 causes structural and functional remodelling in vascular disease, so could be a new therapeutic target.
A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.